COVID-19 Monoclonal Antibody Therapeutics Information for Providers
Recently, bamlanvimab, casirivimab/imdevimab, and bamlanivimab/etesevimab were granted emergency use authorization for the treatment of mild to moderate COVID-19. Until the national supply of these monoclonal antibodies (mAbs) is sufficient, the Iowa Department of Public Health and the United States government will help facilitate allocation across Iowa.
Find a COVID-19 Monoclonal Antibody Provider
HHS mAb Site Locator NICA mAb Site Locator
Request COVID-19 Monoclonal Antibodies
On March 24, 2021, the United States government and Eli Lilly and Company discontinued distribution of bamlanivimab alone due to resistance to variant strains. Bamlanivimab/etesevimab and casirivimab/imdevimab remain available at no cost to providers. Providers can submit a request to receive monoclonal antibodies here. By submitting a request, sites are required to:
- Provide AmerisourceBergen with board of pharmacy license or physician letter of authorization
- Attest to their designated class of trade and that they will administer authorized product according to the EUA
- Provide utilization data via Teletracking or NHSN
Additional information on the ordering process can be found here.
COVID-19 Monoclonal Antibodies Webinar
IDPH hosted a COVID-19 monoclonal antibodies webinar on February 11, 2021 from 10-11 AM CT. Lisa Mascardo, PharmD, FASHP (University of Iowa Health Care) and Kathy Stone, PharmD, RPh, BCSCP (CHI Health Missouri Valley):
- Discussed how to implement an outpatient monoclonal antibody infusion service within an established healthcare organization.
- Described how to access bamlanivimab and/or casirivimab/imdevimab and identified the appropriate contact(s) who can assist with the process.
- Listed strategies to increase provider awareness and patient acceptance of COVID-19 monoclonal antibody therapies.
- Identified anecdotal treatment trends and outcomes realized by sites that have already implemented infusion services for monoclonal antibodies.
- Discussed opportunities for treating long-term care residents with COVID-19 monoclonal antibodies.
Bamlanivimab (Eli Lilly)
Bamlanivimab/Etesevimab (Eli Lilly)